Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

A broadly acting KRAS Inhibitor, TEB-17231, robustly blocks tumor growth and overcomes KRASG12C inhibitor mediated resistance SHANGHAI, March 21, 2023 /PRNewswire/ -- 280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced ...

2023-03-21 20:00 1322

Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

SUZHOU, China, March 21, 2023 /PRNewswire/ -- The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential and representative of all dermatologic associations, ...

2023-03-21 15:22 1305

Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia

TAIZHOU, China, March 21, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus (SARS-CoV-2) outbreak, the Company was granted an...

2023-03-21 13:59 2510

BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications

YANTAI, China, March 21, 2023 /PRNewswire/ -- Luye Pharma Group today announced that the Biologics License Application (BLA) for BA1102 (Denosumab Injection), a biosimilar for the oncology indications developed by its subsidiary Boan Biotech, has been accepted inChina by the Center for Drug Evalu...

2023-03-21 13:46 2130

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, March 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology ...

2023-03-21 08:00 3196

Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in the discovery and development of advanced RNAi thera...

2023-03-20 23:27 2254

Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call

SUZHOU, China, March 20, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2022 annual results release conference call onMarch 31, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, r...

2023-03-20 21:12 1829

Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space

LISBON, Portugal, March 20, 2023 /PRNewswire/ -- Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® plat...

2023-03-20 21:00 1439

CNEY Wins a Large Activated Carbon Order

LISHUI, China, March 20, 2023 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY", or the "Company") today announced that its wholly-owned subsidiary, Zhejiang CN Energy New Materials Co., Ltd., has recently signed a contract to supply its high-quality wood-based activated carbon to a bu...

2023-03-20 20:30 1717

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results ...

2023-03-20 20:00 1827

Guo Guangchang Stresses Healthy Corporate Development and Expresses Full Confidence in the Future

HONG KONG, March 20, 2023 /PRNewswire/ -- On 17 and 18 March, Guo Guangchang, Chairman of Fosun International, attended the 23rd Annual Conference of Yabuli China Entrepreneurs Forum 2023, and the 6th Shanghai Forum Themed Zhejiang Entrepreneurs in the World & the 11th Member Representative Confe...

2023-03-20 17:12 2189

ETANA HAS SECURED FINANCING FROM DEG, EAST VENTURES AND OTHER GLOBAL INVESTORS

JAKARTA, Indonesia, March 20, 2023 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. This round of financing will be used for fu...

2023-03-20 15:22 2715

ETANA HAS SECURED FINANCING FROM DEG, EAST VENTURES AND OTHER GLOBAL INVESTORS

Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting

– Five posters will showcase progress with multiple preclinical and clinical programs, including the clinical results ofATG-008 (mTORC1/2 inhibitor) and preclinical data ofATG-031 (anti-CD24 monoclonal antibody), ATG-037 (small molecule CD73 inhibitor), ATG-017 (ERK1/2 inhibitor), and ATG-034 (L...

2023-03-20 15:20 1759

Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'

SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...

2023-03-17 21:00 3292

Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...

2023-03-17 19:25 2875

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

BEIJING, March 17, 2023 /PRNewswire/ -- According the latest data released at the Clinical Trials Implied Approval section on the website ofChina's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") h...

2023-03-17 14:56 1841

YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ

YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...

2023-03-17 04:30 2286

Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients

SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...

2023-03-16 21:00 1644

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 goze...

2023-03-16 20:28 1676

Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals

Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism...

2023-03-16 16:12 4161

Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals

1 ... 77 78 798081 82 83 ... 294